Results for “hyperglycemia”

Diabetes Mellitus

** Diabetes mellitus is a chronic endocrine disorder marked by persistently elevated blood glucose due to insufficient insulin production, insulin resistance, or both, leading to systemic complications if not properly managed. **CONTENT:** ## Overview Diabetes mellitus, often simply called **diabetes**, comprises a group of metabolic diseases in which the body cannot maintain normal glucose homeostasis. Glucose is the primary fuel for cells, and its regulation depends on the hormone **insulin**, secreted by the pancreatic β‑cells. In **type 1 diabetes**, an autoimmune attack destroys these β‑cells, resulting in little or no insulin. In **type 2 diabetes**, the majority of cases worldwide, the pancreas initially produces insulin but peripheral tissues become **insulin‑resistant**, forcing the organ to work harder until it eventually fails. A third, less common form—**gestational diabetes**—arises during pregnancy and usually resolves after delivery, though it raises future risk for both mother and child. Classic clinical features are the “three Ps”: **polydipsia** (excessive thirst), **polyuria** (frequent urination), and **polyphagia** (increased hunger), often accompanied by unintentional **weight loss**, blurred vision, and fatigue. Diagnosis relies on laboratory criteria such as fasting plasma glucose ≥126 mg/dL, a 2‑hour oral glucose tolerance test ≥200 mg/dL, or an HbA1c ≥6.5 %. If left untreated, chronic hyperglycemia damages blood vessels and nerves, precipitating a spectrum of **microvascular** (retinopathy, nephropathy, neuropathy) and **macrovascular** (coronary artery disease, stroke, peripheral arterial disease) complications. These sequelae account for the disease’s high mortality: roughly **4.2 million deaths** per year worldwide, with about **1.5 million** directly attributable to untreated or poorly controlled diabetes. Early detection, lifestyle modification, and individualized pharmacotherapy are essential to prevent or delay these outcomes. **Anyone experiencing persistent symptoms or at high risk (e.g., family history, obesity, sedentary lifestyle) should seek professional medical evaluation promptly.** ## History/Background The earliest written record of diabetes dates to an Egyptian papyrus (c. 1500 BC) describing “excessive urination.” The term “diabetes” (Greek for “siphon”) was coined by the physician **Aretaeus of Cappadocia** in the 2nd century AD, while **Madhava** of India noted the sweet taste of urine in the 6th century. In 1869, **Paul Langerhans** identified the pancreatic islets (now called **Langerhans islets**) that later proved to be the source of insulin. The breakthrough came in 1921–1922 when **Frederick Banting**, **Charles Best**, and **John Macleod** isolated insulin, enabling life‑saving therapy for type 1 diabetes. The mid‑20th century saw the rise of **type 2 diabetes** as a public health issue, linked to urbanization, dietary changes, and obesity. The **World Health Organization** (WHO) officially recognized diabetes as a global epidemic in the 1990s, prompting the first **International Diabetes Federation (IDF)** conference in 1999. Since then, diagnostic criteria have been refined (e.g., introduction of HbA1c as a diagnostic test in 2010) and novel drug classes—**metformin**, **GLP‑1 receptor agonists**, **SGLT2 inhibitors**—have expanded therapeutic options. ## Key Information - **Classification:** Type 1, Type 2, Gestational, and specific monogenic forms (MODY, neonatal diabetes). - **Epidemiology:** Over 537 million adults (≈ 10 % of the global population) live with diabetes; prevalence is rising fastest in low‑ and middle‑income countries. - **Pathophysiology:** - *Insulin deficiency*: autoimmune β‑cell destruction (type 1) or β‑cell exhaustion (type 2). - *Insulin resistance*: impaired signaling in muscle, adipose, and hepatic tissue, often driven by excess adiposity and inflammatory cytokines. - **Diagnostic thresholds:** Fasting glucose ≥126 mg/dL, 2‑hour OGTT ≥200 mg/dL, HbA1c ≥6.5 %, or random glucose ≥200 mg/dL with classic symptoms. - **Management pillars:** 1. **Lifestyle:** balanced diet (Mediterranean or DASH patterns), regular aerobic and resistance exercise, weight control. 2. **Pharmacotherapy:** metformin first‑line for type 2; insulin for type 1 and advanced type 2; adjunct agents (SGLT2 inhibitors, GLP‑1 agonists) for cardiovascular/renal protection. 3. **Monitoring:** self‑monitoring of blood glucose (SMBG), periodic HbA1c, blood pressure, lipid profile, and screening for complications (annual retinal exam, urine albumin, foot exam). - **Complications:** - *Microvascular*: diabetic retinopathy (leading cause of blindness), diabetic nephropathy (major cause of end‑stage renal disease), peripheral neuropathy (risk of foot ulcers). - *Macrovascular*: accelerated atherosclerosis, increased risk of myocardial infarction and stroke. - **Prevention:** Primary prevention focuses on obesity reduction, physical activity, and dietary quality; secondary prevention emphasizes early detection and tight glycemic control. ## Significance Diabetes mellitus is a **public health priority** because it intersects with virtually every organ system and amplifies the burden of cardiovascular disease, the leading cause of death worldwide. Economically, the disease imposes staggering costs—estimated at **US $966 billion** in 2021—through direct medical expenses and lost productivity. The advent of newer drug classes that confer **cardiorenal protection** has reshaped treatment algorithms, underscoring the importance of a **multidisciplinary approach** involving endocrinologists, primary care physicians, dietitians, diabetes educators, and mental‑health professionals. Beyond the clinical realm, diabetes drives research innovation: **continuous glucose monitoring (CGM)**, **automated insulin delivery (“artificial pancreas”)**, and **gene‑editing therapies** for monogenic forms are rapidly moving from bench to bedside. Public‑health initiatives such as the WHO’s **Global Diabetes Compact** aim to halve premature deaths from diabetes by 2030, emphasizing early screening, equitable access to medicines, and health‑promoting policies. **For anyone suspecting diabetes or managing the condition, regular follow‑up with a qualified health professional is essential** to tailor therapy, monitor for complications, and adjust lifestyle measures. Early, evidence‑based intervention can dramatically improve quality of life and longevity. **INFOBOX:** - Name: Diabetes mellitus - Type: Chronic endocrine/metabolic disorder - Date: First clinical description c. 1500 BC; modern insulin therapy 1922 - Location: Worldwide (global prevalence) - Known For: Persistent hyperglycemia, insulin deficiency or resistance, and systemic complications **TAGS:** diabetes, insulin, hyperglycemia, type 1 diabetes, type 2 diabetes, metabolic disease, chronic illness, public health